| アブストラクト | There are limited real-world data on the treatment practices and healthcare resource utilization associated with chronic lymphocytic leukemia (CLL) in Japan. In this study (CLIMBER-DBR), we performed retrospective analyses of the Japanese Medical Data Vision database, and extracted data for 2562 patients with newly diagnosed CLL (CLL-1 cohort) and 930 patients receiving CLL treatment (CLL-2 cohort) registered between March 1, 2013 and February 28, 2018. The median follow-up in the CLL-1 cohort was 721 (quartile 1-3: 363-1267) days and the median time to initial (first-line) treatment was 1331 (quartile 1-3: 189-not reached) days. In the CLL-2 cohort, the most frequently used regimens were fludarabine alone (17.7%), cyclophosphamide alone (13.7%), and bendamustine/rituximab (8.2%). The median (quartile 1-3) times to second-line and third-line treatments were 1066 (273-not reached) and 1795 (631-not reached) days, respectively. The CLIMBER-DBR was the first database research study to assess current treatment practices for CLL in Japan, where the treatment patterns were driven by the approval/reimbursement status of drugs in the study period. Our study provides an important benchmark for future studies of CLL in Japan. |
|---|
| ジャーナル名 | Journal of clinical and experimental hematopathology : JCEH |
|---|
| 投稿日 | 2021/6/8 |
|---|
| 投稿者 | Takizawa, Jun; Izutsu, Koji; Nagai, Hirokazu; Fukase, Kenjiro; Nakamura, Maki; Jinushi, Masahisa; Suzumiya, Junji |
|---|
| 組織名 | Department of Hematology, Endocrinology and Metabolism, Niigata University;Faculty of Medicine, Niigata, Japan.;Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.;Department of Hematology, National Hospital Organization Nagoya Medical Center,;Nagoya, Japan.;AstraZeneca K.K., Osaka, Japan.;Innovative Cancer Center, Shimane University Hospital, Izumo, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34092721/ |
|---|
